Uniqure NV Aktie - UQ1

Rendering Error

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

13,305

Gebot

13,105

Fragen

13,485

Volumen

0,00

0,00 Tagesbereich 0,00

3,548 52-Wochen-Bereich 18,38

Handelsende

13,305

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

420

Finanzvolumen

VWAP

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress ~ Announced alignment with the U.S. Food and Drug Administration...

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its...

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the...

uniQure Announces Pricing of its Public Offering

uniQure Announces Pricing of its Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE...

uniQure Announces Proposed Public Offering

uniQure Announces Proposed Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a...

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug...

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.95	7.68919465803	12.355	13.47	12.02	1264	12.96851266	DE
4	1.945	17.1214788732	11.36	13.47	9.734	580	12.38148793	DE
12	-3.585	-21.2255772647	16.89	18.38	9.734	420	13.56387057	DE
26	8.97	206.920415225	4.335	18.38	4.11	1044	12.15985784	DE
52	8.395	170.977596741	4.91	18.38	3.548	1187	9.36939307	DE
156	-2.315	-14.8207426376	15.62	25.61	3.548	915	8.75730566	DE
260	-18.155	-57.70820089	31.46	32.78	3.548	571	9.90389672	DE

UQ1 - Frequently Asked Questions (FAQ)

What is the current Uniqure NV share price?

The current share price of Uniqure NV is 13,305 €

What is the 1 year trading range for Uniqure NV share price?

Uniqure NV has traded in the range of 3,548 € to 18,38 € during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
4NM1China Evergrande New Energy Vehicle Group Limited	0,0288 € (102,82%)	40,3k
AMIMedondo Holding AG	0,498 € (91,54%)	110
MBQMobotix AG	0,915 € (61,95%)	51,03k
8XJAfrican Gold Limited	0,0675 € (56,98%)	2,5k
L7C2Windfall Geotek Inc	0,011 € (29,41%)	1,31k
EJ7Energy Resources of Australia	0,001 € (-33,33%)	999,99k
DW8Tantalex Lithium Resources Corp	0,0105 € (-30,00%)	849
E3O1Nexoptic Technology Corp	0,006 € (-29,41%)	4,77k
K1SNKlondike Silver Corporation	0,013 € (-27,78%)	100k
VOPInvestigator Resources Ltd	0,0105 € (-25,00%)	447
DMLSayona Mining Limited	0,0115 € (0,00%)	3,1M
D7GNel ASA	0,233 € (-4,70%)	2,42M
DMJDynaCERT Inc	0,1285 € (11,74%)	2,22M
FMKEcograf Limited	0,263 € (12,88%)	2,08M
PF8European Lithium Limited	0,0246 € (-4,65%)	1,23M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Uniqure NV (UQ1)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

UQ1 Neueste Nachrichten

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

UQ1 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Uniqure NV (UQ1) Börsenkurse

Uniqure NV (UQ1)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

UQ1 Neueste Nachrichten

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

UQ1 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen